NewsTuesday, 08. July 2014
PARI SINUS Hands-on Course: “Pulsating Aerosol for Upper Airways in CF”
37th European Cystic Fibrosis Cystic Fibrosis
Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions. Conference from 11th to 14th June 2014 in Gothenburg, Sweden
The pulsating aerosol aerosol
An aerosol is a colloid of fine solid particles or liquid droplets, in air or another gas. generated by PARI SINUS enables the precise deposition of active ingredient in the paranasal cavities and as such offers a gentle and convincing option for the treatment of acute and chronic rhinosinusitis. Studies performed to date demonstrate impressive symptom relief as well as a clear improvement in quality of life. According to Dr Mainz from the University Hospital in Jena, around 65% of cystic fibrosis cystic fibrosis
Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions. (CF) patients suffer from intermittent or chronic rhinosinusitis (CRS).
This year‘s European Cystic Fibrosis Cystic Fibrosis
Genetic disorder that affects most critically the lungs, leading to thick, viscous secretions. Conference in Gothenburg was host to the first PARI SINUS “Hands-on Course”. The Course, chaired by Fred Lessire from the Zeepreventorium in De Haan, Belgium, gave the over 100 participants the opportunity to inhale with PARI SINUS and to judge its handling, ease of use and efficacy for themselves. 82% of those participants who completed the questionnaire after the workshop, rated their overall impression as either “excellent” or “very good.” In a brief interview after the Course, Fred Lessire himself spoke of a unique device which enabled a deposition of the active ingredient in the paranasal cavities at a price which justified it being used to also treat patients in the home environment.
Participants furthermore had the opportunity to inhale different strengths of saline solution with PARI SINUS. Alison Gates, Specialist Adult CF Physio from Churchill Hospital in Oxford, UK reported afterwards “The 6% hypertonic saline wasn’t uncomfortable and my nose felt clearer after the inhalation session”.
In addition to the Proof-of-Concept and pilot studies already available, a study amongst CF patients with concomitant CRS to evaluate the inhalation of 6.0% saline to the paranasal cavities is currently being evaluated by Dr Mainz and his team at the University Hospital in Jena, Germany. More details on this study can be found at: